Human Bnp-32 Nesiri...

Human Bnp-32 Nesiritide Brain Natriuretic Peptide for Heart Failure

Human Bnp-32 Nesiritide Brain Natriuretic Peptide for Heart Failure

Min.Order / FOB Price:Get Latest Price

1 Gram

Negotiable

  • Min.Order :1 Gram
  • Purity: ≥98%
  • Payment Terms : L/C,T/T

Keywords

Nesiritide, Несиритид,nesiritida,nésiritide Acetato de nesiritida,Несиритид ацетат,nesiritida Acétate de nésiritide, Acetato de nesiritida

Quick Details

  • Appearance:white to off white
  • Application: Nesiritide should be considered for patients presenting with acutely typical or useful decompensated heart failure, especially those with dyspnea at rest or with minimal activity.
  • PackAge:Aluminum Foil Bag
  • ProductionCapacity:500|Kilogram|Year
  • Storage:2-8 degree
  • Transportation:Cold chain and cool storage delivery fro options

Superiority:

The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reachease to 500kg with 3 main factory sites.

Details:

 

Nesiritide  (BNP-32), know as B-Type Natriuretic Peptide, BNP 32, Brain Natriuretic Peptide 32, Type-B Natriuretic Peptide, Ventricular Natriuretic Peptide, B type.

Product Description

Human BNP serves to compensate for deteriorating cardiac function causing preload and afterload reductions, natriuresis, diuresis, suppression of the renin-angiotensin-aldosterone system (RAAS) and endothelin-1, and lowering of norepinephrine. Based on its unique pharmacologic profile, nesiritide results in clinically significant balanced vasodilation of arteries and veins, and may be well suited for patients presenting with various scenarios of decompensated CHF usually due to volume overload (NYHA classes II-IV).
Unlike nitroglycerin, tachyphylaxis did not appear to occur with Natrecor. The complete efficacy profile of nesiritide included preload reduction (PCWP and RAP), reductions in pulmonary artery pressures, afterload reduction (systemic vascular resistance), and increases in cardiac index and stroke volume index (which are dose-dependent and not the result of a direct inotropic effect), without increasing heart rate.
Unlike inotropes, the beneficial hemodynamic effects produced by nesiritide do not cause an increase in myocardial oxygen consumption (MVO2), an important consideration for patients with acutely decompensated heart failure. Because Nesiritide is not an inotrope, it does not affect myocardial contractility, as does a beta-adrenergic receptor agonist, or a phosphodiesterase III inhibitor. As a result, nesiritide is not arrhythmogenic.  


PRAMETERS
Name: Nesiritide  (BNP-32) 

Cas No:
124584-08-3

Formula: C143H244N50O42S4

Molecular:3464.04

Purity:98%

Appearance: white powder

Source: synthetic

FAQ

Q1. Are you a trade company or manufactures

A: We are an GMP approved manufacturer specialized in peptides API products, OEM is available, Key products have obtained USDMF and EDMF. Production lines passed US and EU Authorities audit.

Q2. What is your MOQ

A: We support trial order, 1g is min. 

Q3. What is your delivery date

A: Can be shipped within 2days after payment.

Q4. What is your payment term

A: T/T, LC.

Q5. Which country is your products sold

A: Our products sold worldwide expecially to Europe, North America, South America and Africa.

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View